Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily p...
Uloženo v:
| Vydáno v: | Clinical lymphoma, myeloma and leukemia Ročník 22; číslo 7; s. 460 - 473 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
01.07.2022
|
| Témata: | |
| ISSN: | 2152-2650, 2152-2669, 2152-2669 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily pretreated patients with relapsed and refractory multiple myeloma, with a focus on the optimal management of patients with MM refractory to lenalidomide, bortezomib, and in some cases, daratumumab or an anti-CD38 monoclonal antibody. Data from recent clinical trials of immunomodulatory agents (pomalidomide), proteasome inhibitors (PIs; carfilzomib and ixazomib), monoclonal antibodies (elotuzumab, daratumumab, and isatuximab), and other novel therapies (including panobinostat-based therapy) are summarized. We also provide potential therapeutic strategies for patients according to different treatment histories, and include case studies to illustrate the practical use of various treatment options in a clinical setting. Regimens containing pomalidomide, elotuzumab, next-generation PIs, panobinostat, or selinexor may provide effective treatment options in patients with triple-refractory disease. The choice of agents used, and combinations thereof should be individualized as well as strategically planned from early- to late-stage relapse. |
|---|---|
| AbstractList | Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily pretreated patients with relapsed and refractory multiple myeloma, with a focus on the optimal management of patients with MM refractory to lenalidomide, bortezomib, and in some cases, daratumumab or an anti-CD38 monoclonal antibody. Data from recent clinical trials of immunomodulatory agents (pomalidomide), proteasome inhibitors (PIs; carfilzomib and ixazomib), monoclonal antibodies (elotuzumab, daratumumab, and isatuximab), and other novel therapies (including panobinostat-based therapy) are summarized. We also provide potential therapeutic strategies for patients according to different treatment histories, and include case studies to illustrate the practical use of various treatment options in a clinical setting. Regimens containing pomalidomide, elotuzumab, next-generation PIs, panobinostat, or selinexor may provide effective treatment options in patients with triple-refractory disease. The choice of agents used, and combinations thereof should be individualized as well as strategically planned from early- to late-stage relapse. Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily pretreated patients with relapsed and refractory multiple myeloma, with a focus on the optimal management of patients with MM refractory to lenalidomide, bortezomib, and in some cases, daratumumab or an anti-CD38 monoclonal antibody. Data from recent clinical trials of immunomodulatory agents (pomalidomide), proteasome inhibitors (PIs; carfilzomib and ixazomib), monoclonal antibodies (elotuzumab, daratumumab, and isatuximab), and other novel therapies (including panobinostat-based therapy) are summarized. We also provide potential therapeutic strategies for patients according to different treatment histories, and include case studies to illustrate the practical use of various treatment options in a clinical setting. Regimens containing pomalidomide, elotuzumab, next-generation PIs, panobinostat, or selinexor may provide effective treatment options in patients with triple-refractory disease. The choice of agents used, and combinations thereof should be individualized as well as strategically planned from early- to late-stage relapse.Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily pretreated patients with relapsed and refractory multiple myeloma, with a focus on the optimal management of patients with MM refractory to lenalidomide, bortezomib, and in some cases, daratumumab or an anti-CD38 monoclonal antibody. Data from recent clinical trials of immunomodulatory agents (pomalidomide), proteasome inhibitors (PIs; carfilzomib and ixazomib), monoclonal antibodies (elotuzumab, daratumumab, and isatuximab), and other novel therapies (including panobinostat-based therapy) are summarized. We also provide potential therapeutic strategies for patients according to different treatment histories, and include case studies to illustrate the practical use of various treatment options in a clinical setting. Regimens containing pomalidomide, elotuzumab, next-generation PIs, panobinostat, or selinexor may provide effective treatment options in patients with triple-refractory disease. The choice of agents used, and combinations thereof should be individualized as well as strategically planned from early- to late-stage relapse. |
| Author | Richardson, Paul Dimopoulos, Meletios-Athanasios Lonial, Sagar |
| Author_xml | – sequence: 1 givenname: Meletios-Athanasios orcidid: 0000-0001-8990-3254 surname: Dimopoulos fullname: Dimopoulos, Meletios-Athanasios email: mdimop@med.uoa.gr organization: National and Kapodistrian University of Athens, Athens, Greece – sequence: 2 givenname: Paul surname: Richardson fullname: Richardson, Paul organization: Dana-Farber Cancer Institute, Boston, MA – sequence: 3 givenname: Sagar surname: Lonial fullname: Lonial, Sagar organization: Winship Cancer Institute, Emory University, Atlanta, GA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35148975$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkE1r3DAQhkVJaL76B3ooOvayW0le2VbppYS0KSQkhIQexXg8ptrKH5W0Af_7ymzSQw4pDMwH7zOH54QdDONAjL2XYi2FLD9t1-h7v1ZCqbWQueQbdqykVitVlubg36zFETuJcStEJYQ0b9lRoeWmNpU-ZvY-EKSehsRvpuTGIfJuDPwWksu3yH-69ItfEjw6P_PbQGmJU8vvyMMU8wDDsnQBMI1h5tc7n9zkiV_P5McezthhBz7Su6d-yh6-XdyfX66ubr7_OP96tcKNqNKKOjQIGqqiAK1bBNOirjtVNLppRKVMWzcFFNiYCgpRU4HYGhCYOV3WoilO2cf93ymMf3YUk-1dRPIeBhp30apS1crUG13m6Ien6K7pqbVTcD2E2T5LyYF6H8Awxhios-gSLHJSAOetFHbxb7d28W8X_1bIXDKj6gX6_P1V6Mseoizo0VGwEbN9pNYFwmTb0b2Of36Bo3eDQ_C_af4f_BcVELPp |
| CitedBy_id | crossref_primary_10_1002_med_21972 crossref_primary_10_1038_s41375_025_02736_x crossref_primary_10_1080_03007995_2024_2391112 crossref_primary_10_1080_14796694_2025_2460419 crossref_primary_10_3389_fmed_2023_1271657 crossref_primary_10_1371_journal_pone_0308672 crossref_primary_10_1016_j_ymthe_2023_12_018 crossref_primary_10_1038_s41598_025_97584_1 crossref_primary_10_1016_j_clml_2025_05_006 crossref_primary_10_3390_cells13100879 crossref_primary_10_1371_journal_pone_0315932 crossref_primary_10_3892_etm_2023_12025 crossref_primary_10_3390_ijms232416162 crossref_primary_10_46989_001c_137860 crossref_primary_10_1038_s41408_024_00988_x crossref_primary_10_1056_NEJMoa2303194 crossref_primary_10_1038_s41408_023_00804_y crossref_primary_10_1080_10428194_2024_2422843 crossref_primary_10_1016_j_ejca_2024_115157 crossref_primary_10_1056_NEJMoa2213614 crossref_primary_10_1007_s40259_024_00688_9 crossref_primary_10_1016_j_jtct_2022_10_022 crossref_primary_10_3390_cancers16173063 crossref_primary_10_1182_blood_2024024582 crossref_primary_10_1097_CM9_0000000000003649 crossref_primary_10_1111_ejh_14365 crossref_primary_10_1016_j_seminoncol_2025_152390 crossref_primary_10_1038_s41598_025_96565_8 crossref_primary_10_1080_10428194_2023_2235042 crossref_primary_10_1158_2326_6066_CIR_23_0839 crossref_primary_10_1016_j_jtct_2024_05_011 crossref_primary_10_3389_pore_2022_1610645 |
| Cites_doi | 10.1016/S1470-2045(20)30680-X 10.1016/j.clml.2019.09.621 10.1200/JCO.2020.38.15_suppl.8501 10.1182/blood.2019000722 10.1038/bcj.2015.66 10.1038/leu.2015.240 10.1111/bjh.15716 10.1038/leu.2014.238 10.1097/01.HS9.0000563756.72895.a3 10.1177/1060028019892643 10.1038/s41375-020-0813-1 10.1182/blood-2020-140526 10.1016/j.clml.2019.04.018 10.1038/leu.2012.119 10.3322/caac.21332 10.1158/1078-0432.CCR-07-4246 10.1200/JCO.20.02259 10.1182/blood-2020-138831 10.1200/JCO.2013.48.7934 10.1200/JCO.2020.38.15_suppl.8504 10.1016/S1470-2045(19)30152-4 10.1038/s41375-018-0038-8 10.1200/JCO.2020.38.15_suppl.8502 10.1158/1535-7163.MCT-17-0998 10.1200/JCO.2020.38.15_suppl.8505 10.1038/bmt.2015.307 10.3324/haematol.2014.119735 10.1016/S1470-2045(15)00464-7 10.1038/s41408-018-0141-0 10.1111/bjh.13905 10.1038/s41408-019-0219-3 10.1179/1607845414Y.0000000218 10.1182/blood-2013-11-538835 10.1182/blood-2019-126660 10.1016/S0145-2126(12)70003-6 10.1182/blood-2017-05-785246 10.1007/s00277-018-3546-8 10.1056/NEJMoa1903455 10.1016/j.clml.2019.12.013 10.1111/bjh.15551 10.1016/S0140-6736(20)30734-0 10.1038/leu.2017.138 10.1182/blood-2016-02-700872 10.1111/bjh.15969 10.1016/j.bbmt.2015.03.026 10.1056/NEJMoa1805762 10.1016/S0140-6736(15)01120-4 10.1182/asheducation-2017.1.508 10.3389/fimmu.2020.01155 10.1182/blood-2020-140697 10.1182/blood-2020-136307 10.1182/blood-2020-140410 10.1002/cncr.32178 10.1016/S1470-2045(13)70380-2 10.1182/blood-2020-134189 10.1038/leu.2015.356 10.1200/JCO.2020.38.15_suppl.8500 10.1182/blood-2020-137743 10.1016/S2352-3026(20)30070-3 10.1182/blood-2013-01-481325 10.1038/s41375-019-0435-7 10.1182/blood-2019-122895 10.1200/JCO.19.02657 10.4049/jimmunol.1003032 10.1186/s12943-019-1092-1 10.1007/s00432-020-03365-w 10.1056/NEJMoa2024850 10.1016/S1470-2045(19)30788-0 10.1182/blood-2017-10-809293 10.1182/blood-2020-136360 10.1056/NEJMoa1411321 10.1038/leu.2014.140 10.1007/s40123-020-00280-8 10.1182/blood-2020-137602 10.3390/cancers12061473 10.1007/s00262-013-1493-8 10.1182/blood-2018-99-114029 10.1182/blood-2020-135874 10.1200/JCO.18.02096 10.1182/blood-2007-08-107292 10.1111/j.1445-5994.2012.02867.x 10.1182/blood-2019-132629 10.1182/blood-2015-05-643320 10.1182/blood-2020-134383 10.1056/NEJMoa1516282 10.1182/blood-2019-129021 10.1182/blood-2019-126015 10.1182/blood-2014-11-611426 10.1093/annonc/mdx096 10.1016/S0140-6736(19)32556-5 10.1016/S2352-3026(16)30165-X |
| ContentType | Journal Article |
| Copyright | 2022 The Authors Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 The Authors – notice: Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.clml.2022.01.011 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2152-2669 |
| EndPage | 473 |
| ExternalDocumentID | 35148975 10_1016_j_clml_2022_01_011 S2152265022000155 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 4.4 457 4G. 53G 5VS 6PF 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFKBS EFLBG EJD EMOBN F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 ROL SDF SEL SES SPCBC SSH SSZ T5K TEORI XH2 Z5R ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EMB LCYCR SV3 AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c407t-efc9ca5a733a55dca9dc58f23b5bb0729d8b3a3cb97a308e3ccd9a0cefc5680b3 |
| ISICitedReferencesCount | 35 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000823079800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2152-2650 2152-2669 |
| IngestDate | Sun Nov 09 13:11:06 EST 2025 Wed Feb 19 02:27:10 EST 2025 Tue Nov 18 22:13:10 EST 2025 Sat Nov 29 02:17:38 EST 2025 Fri Feb 23 02:39:56 EST 2024 Tue Oct 14 19:30:16 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Immunomodulatory drugs Multiple myeloma Heavily pretreated Monoclonal antibodies Anti-CD38 antibody Pomalidomide Relapsed/refractory Proteasome inhibitors Elotuzumab |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c407t-efc9ca5a733a55dca9dc58f23b5bb0729d8b3a3cb97a308e3ccd9a0cefc5680b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-8990-3254 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.clml.2022.01.011 |
| PMID | 35148975 |
| PQID | 2628298456 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_2628298456 pubmed_primary_35148975 crossref_citationtrail_10_1016_j_clml_2022_01_011 crossref_primary_10_1016_j_clml_2022_01_011 elsevier_sciencedirect_doi_10_1016_j_clml_2022_01_011 elsevier_clinicalkey_doi_10_1016_j_clml_2022_01_011 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-01 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical lymphoma, myeloma and leukemia |
| PublicationTitleAlternate | Clin Lymphoma Myeloma Leuk |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Dimopoulos, Dytfeld, Grosicki (bib0032) 2018; 379 Usmani, Quach, Mateos (bib0062) 2019; 134 Chari, Martinez-Lopez, Mateos (bib0061) 2019; 134 Laubach, Garderet, Mahindra (bib0109) 2016; 30 Moreau, San Miguel, Sonneveld (bib0001) 2017; 28 Goldschmidt, Ashcroft, Szabo, Garderet (bib0012) 2019; 98 Borrello (bib0004) 2012; 36 Dimopoulos, Quach, Mateos (bib0063) 2020; 396 Bristol Myers Squibb. Empliciti Gavriatopoulou, Kastritis, Ntanasis-Stathopoulos (bib0112) 2018; 131 (pomalidomide) Prescribing Information. Available at (ixazomib) Prescribing Information. Available at Berdeja, Madduri, Usmani (bib0089) 2020; 38 Richardson, Oriol, Larocca (bib0102) 2021; 39 San-Miguel, Weisel, Moreau (bib0025) 2013; 14 Raedler (bib0044) 2016; 9 Amin, Yip, Minvielle (bib0006) 2014; 28 Moreau, Masszi, Grzasko (bib0046) 2016; 374 Palumbo, Rajkumar, San Miguel (bib0013) 2014; 32 Sanofi-Aventis Groupe. Sarclisa Chari, Vogl, Gavriatopoulou (bib0070) 2019; 381 Mailankody, Jakubowiak, Htut (bib0087) 2020; 38 Kansagra, Lin, Berdeja (bib0091) 2020; 136 Chow, Lee, Hiwase, To, Horvath (bib0016) 2013; 43 Madduri, Berdeja, Usmani (bib0084) 2020; 136 Celgene. Imnovid Hussain, Robinson, Hamadeh (bib0111) 2019; 186 Dimopoulos, Palumbo, Corradini (bib0026) 2016; 128 (isatuximab) Prescribing Information. Available at Nooka A.K., Stockerl-Goldstein K., Quach H., DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). Oral presentation at: the American Society of Clinical Oncology Annual Meeting; May 29–31, 2020. Abstract 8502. Bjorklund, Lu, Kang (bib0019) 2015; 5 van de Donk, Popat, Larsen (bib0100) 2020; 136 Sanofi Genzyme. Sarclisa Bristol Myers Squibb. ABECMA Cornell, Kassim (bib0005) 2016; 51 Mikhael (bib0017) 2020; 20 Chen C.I., Bahlis N.J., Gasparetto C., Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM). Oral presentation at: the American Society of Hematology (ASH) Annual Meeting & Exposition. December 5–8, 2020. Abstract 726. Moreau, Harrison, Cavo (bib0103) 2019; 134 GlaxoSmithKline. Blenrep Richardson, Oriol, Beksac (bib0028) 2019; 20 Karyopharm Europe GmbH. Nexpovio GlaxoSmithKline (Ireland) Limited. Blenrep Takeda Pharmaceutical Company Limited. Ninlaro (daratumumab) Prescribing Information. Available at (pomalidomide) Summary of Product Characteristics. Available at (selinexor) Summary of Product Characteristics. Available at Costa, Wong, Bermudez (bib0097) 2019; 134 Amgen. Kyprolis Laubach, Schjesvold, Mariz (bib0080) 2021; 22 Dimopoulos, Moreau, Palumbo (bib0039) 2016; 17 Richardson, Siegel, Vij (bib0027) 2014; 123 Topp, Duell, Zugmaier (bib0096) 2020; 38 Hsi, Steinle, Balasa (bib0049) 2008; 14 (isatuximab) Summary of Product Characteristics. Available at Secura Bio. Farydak Richardson, Schlossman, Alsina (bib0079) 2013; 122 Usmani, Mateos, Hungria (bib0059) 2021; 147 Ocio, Fernandez-Lazaro, San-Segundo (bib0022) 2015; 29 (carfilzomib) Summary of Product Characteristics. Available at (panobinostat) Summary of Product Characteristics. Available at Berdeja, Alsina, Shah (bib0090) 2019; 134 Sehgal, Das, Zhang (bib0021) 2015; 125 Dimopoulos M., Delimpasi S., Simonova M., Weekly selinexor, bortezomib, and dexamethasone (SVd) vs. twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. Oral presentation at: the American Society of Clinical Oncology Annual Meeting; May 29–31, 2020. Abstract 8501. Jakubowiak, Jasielec, Rosenbaum (bib0075) 2019; 186 Lin, Zhao, Song, Liu (bib0093) 2019; 18 National Comprehensive Cancer Network. NCCN Guidelines clinical practice guidelines in oncology: Version 2.2021 Multiple Myeloma. Version 2.2021. Available at (daratumumab) Summary of Product Characteristics. Available at Laubach, Schjesvold, Mariz (bib0116) 2020; 136 Accessed July 2, 2020. (carfilzomib) Prescribing Information. Available at: https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf. Accessed August 4, 2021. Lonial, Weiss, Usmani (bib0058) 2016; 387 de Weers, Tai, van der Veer (bib0055) 2011; 186 Chari, Suvannasankha, Fay (bib0034) 2017; 130 Dimopoulos M.A., Terpos E., Boccadaro M., Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Vs. Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020; Abstract 653. Orlowski, Moreau, Niesvizky (bib0040) 2019; 19 Munshi, Anderson, Shah (bib0085) 2021; 384 Sonneveld (bib0011) 2017; 2017 Popat, Brown, Flanagan (bib0081) 2016; 3 Nooka, Joseph, Kaufman (bib0110) 2019; 125 (elotuzumab) Prescribing Information. Available at Sonneveld, Zweegman, Cavo (bib0030) 2018; 132 Alsina, Shah, Raje (bib0088) 2020; 136 (belantamab mafodotin) Summary of Product Characteristics. Available at Lin, Martin, Cohen (bib0092) 2020; 136 Mateos, Nahi, Legiec (bib0060) 2020; 7 Lonial, Lee, Badros (bib0094) 2020; 21 Jiang, Acharya, An (bib0068) 2016; 30 Mikhael, Ismaila, Cheung (bib0008) 2019; 37 (panobinostat) Prescribing Information. Available at Parrish, Rahemtulla, Cavet (bib0015) 2015; 21 Dhakal, D'Souza, Hamadani (bib0048) 2019; 9 Krishnan, Kapoor, Palmer (bib0031) 2018; 32 Takeda Pharma A/S. Ninlaro (ixazomib) Summary of Product Characteristics. Available at (belantamab mafodotin) Prescribing Information. Available at Grajales-Cruz, Arocho, Rose (bib0114) 2019; 134 Accessed June 4, 2021. Oriol, Giraldo, Kotsianidis (bib0014) 2015; 20 Siegel, Miller, Jemal (bib0002) 2016; 66 Gandhi, Cornell, Lakshman (bib0010) 2019; 33 Kurdi, Glavey, Bezman (bib0052) 2018; 17 Dimopoulos M.A., Quach H., Mateos M.-V., Carfilzomib, Dexamethasone, and Daratumumab Vs. Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. Poster presentation at: the American Society of Hematology (ASH) Annual Meeting & Exposition. December 5–8, 2020. Poster 2325. Lonial S., Lee H.C., Badros A., DREAMM-2: Single-agent belantamab mafodotin (Belamaf) in patients with relapsed/refractory multiple myeloma (RRMM) –1-year outcomes by prior therapies. Poster presentation at: the American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020. Poster 1417. Farooq, Degli Esposti, Popat (bib0107) 2020; 9 Salcedo, Lendvai, Mastey (bib0076) 2020; 20 (idecabtagene vicleucel) Prescribing Information. Available at Stewart, Rajkumar, Dimopoulos (bib0043) 2015; 372 Siegel, Schiller, Samaras (bib0036) 2020; 34 Shah, Stadtmauer, Abonour (bib0029) 2015; 126 Janssen. Darzalex National Cancer Institute. Cancer stat facts: myeloma. Available at (selinexor) Prescribing Information. Available at Cho, Lin, Xing (bib0099) 2020; 12 Secura Bio Limited. Farydak Popat, Brown, Flanagan (bib0082) 2019; 185 Celgene. Pomalyst Accessed August 4, 2021. Collins, Bakan, Swartzel (bib0051) 2013; 62 (elotuzumab) Summary of Product Characteristics. Available at Karyopharm. Xpovio Rychak, Mendy, Shi (bib0023) 2016; 172 Richardson, San Miguel, Moreau (bib0115) 2018; 8 Lopez-Girona, Mendy, Ito (bib0020) 2012; 26 Siegel, Schiller, Samaras (bib0037) 2020; 136 Tai, Dillon, Song (bib0050) 2008; 112 Peterson, Orozco, Buege (bib0069) 2020; 54 Berdeja, Hart, Mace (bib0083) 2015; 100 Kumar, Dimopoulos, Kastritis (bib0007) 2017; 31 Dimopoulos, Dytfeld, Grosicki (bib0033) 2019; 2 Becnel, Horowitz, Thomas (bib0113) 2020; 136 Attal, Richardson, Rajkumar (bib0038) 2019; 394 Moreau P., Dimopoulos M., Mikhael J., Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3, randomized, open-label study. Oral presentation at: the European Hematology Association (EHA) Annual Meeting; June 11–14, 2020. Abstract LB2603. Bruins, Zweegman, Mutis, van de Donk (bib0095) 2020; 11 Richardson, Vangsted, Ramasamy (bib0101) 2020; 38 Garfall, Usmani, Mateos (bib0098) 2020; 136 Dimopoulos (10.1016/j.clml.2022.01.011_bib0033) 2019; 2 de Weers (10.1016/j.clml.2022.01.011_bib0055) 2011; 186 Grajales-Cruz (10.1016/j.clml.2022.01.011_bib0114) 2019; 134 Garfall (10.1016/j.clml.2022.01.011_bib0098) 2020; 136 Dimopoulos (10.1016/j.clml.2022.01.011_bib0026) 2016; 128 Raedler (10.1016/j.clml.2022.01.011_bib0044) 2016; 9 Richardson (10.1016/j.clml.2022.01.011_bib0079) 2013; 122 10.1016/j.clml.2022.01.011_bib0024 van de Donk (10.1016/j.clml.2022.01.011_bib0100) 2020; 136 Bjorklund (10.1016/j.clml.2022.01.011_bib0019) 2015; 5 Topp (10.1016/j.clml.2022.01.011_bib0096) 2020; 38 Alsina (10.1016/j.clml.2022.01.011_bib0088) 2020; 136 Gavriatopoulou (10.1016/j.clml.2022.01.011_bib0112) 2018; 131 Gandhi (10.1016/j.clml.2022.01.011_bib0010) 2019; 33 Amin (10.1016/j.clml.2022.01.011_bib0006) 2014; 28 Jiang (10.1016/j.clml.2022.01.011_bib0068) 2016; 30 10.1016/j.clml.2022.01.011_bib0035 Sonneveld (10.1016/j.clml.2022.01.011_bib0011) 2017; 2017 Lin (10.1016/j.clml.2022.01.011_bib0093) 2019; 18 Orlowski (10.1016/j.clml.2022.01.011_bib0040) 2019; 19 Lonial (10.1016/j.clml.2022.01.011_bib0058) 2016; 387 Mailankody (10.1016/j.clml.2022.01.011_bib0087) 2020; 38 10.1016/j.clml.2022.01.011_bib0009 Cho (10.1016/j.clml.2022.01.011_bib0099) 2020; 12 Popat (10.1016/j.clml.2022.01.011_bib0082) 2019; 185 Tai (10.1016/j.clml.2022.01.011_bib0050) 2008; 112 10.1016/j.clml.2022.01.011_bib0086 Oriol (10.1016/j.clml.2022.01.011_bib0014) 2015; 20 Siegel (10.1016/j.clml.2022.01.011_bib0037) 2020; 136 10.1016/j.clml.2022.01.011_bib0003 Berdeja (10.1016/j.clml.2022.01.011_bib0090) 2019; 134 Dimopoulos (10.1016/j.clml.2022.01.011_bib0032) 2018; 379 Moreau (10.1016/j.clml.2022.01.011_bib0103) 2019; 134 Hussain (10.1016/j.clml.2022.01.011_bib0111) 2019; 186 Chari (10.1016/j.clml.2022.01.011_bib0034) 2017; 130 Mikhael (10.1016/j.clml.2022.01.011_bib0017) 2020; 20 10.1016/j.clml.2022.01.011_bib0018 Bruins (10.1016/j.clml.2022.01.011_bib0095) 2020; 11 Attal (10.1016/j.clml.2022.01.011_bib0038) 2019; 394 Kurdi (10.1016/j.clml.2022.01.011_bib0052) 2018; 17 Nooka (10.1016/j.clml.2022.01.011_bib0110) 2019; 125 Richardson (10.1016/j.clml.2022.01.011_bib0027) 2014; 123 Laubach (10.1016/j.clml.2022.01.011_bib0109) 2016; 30 Goldschmidt (10.1016/j.clml.2022.01.011_bib0012) 2019; 98 Rychak (10.1016/j.clml.2022.01.011_bib0023) 2016; 172 Dimopoulos (10.1016/j.clml.2022.01.011_bib0063) 2020; 396 Richardson (10.1016/j.clml.2022.01.011_bib0101) 2020; 38 10.1016/j.clml.2022.01.011_bib0108 Stewart (10.1016/j.clml.2022.01.011_bib0043) 2015; 372 Munshi (10.1016/j.clml.2022.01.011_bib0085) 2021; 384 10.1016/j.clml.2022.01.011_bib0106 Berdeja (10.1016/j.clml.2022.01.011_bib0089) 2020; 38 10.1016/j.clml.2022.01.011_bib0064 Mateos (10.1016/j.clml.2022.01.011_bib0060) 2020; 7 10.1016/j.clml.2022.01.011_bib0105 10.1016/j.clml.2022.01.011_bib0104 Laubach (10.1016/j.clml.2022.01.011_bib0080) 2021; 22 Costa (10.1016/j.clml.2022.01.011_bib0097) 2019; 134 10.1016/j.clml.2022.01.011_bib0067 Collins (10.1016/j.clml.2022.01.011_bib0051) 2013; 62 10.1016/j.clml.2022.01.011_bib0066 10.1016/j.clml.2022.01.011_bib0065 Madduri (10.1016/j.clml.2022.01.011_bib0084) 2020; 136 Sehgal (10.1016/j.clml.2022.01.011_bib0021) 2015; 125 Parrish (10.1016/j.clml.2022.01.011_bib0015) 2015; 21 Lopez-Girona (10.1016/j.clml.2022.01.011_bib0020) 2012; 26 Palumbo (10.1016/j.clml.2022.01.011_bib0013) 2014; 32 Cornell (10.1016/j.clml.2022.01.011_bib0005) 2016; 51 Siegel (10.1016/j.clml.2022.01.011_bib0036) 2020; 34 Hsi (10.1016/j.clml.2022.01.011_bib0049) 2008; 14 10.1016/j.clml.2022.01.011_bib0074 10.1016/j.clml.2022.01.011_bib0073 Laubach (10.1016/j.clml.2022.01.011_bib0116) 2020; 136 Dimopoulos (10.1016/j.clml.2022.01.011_bib0039) 2016; 17 10.1016/j.clml.2022.01.011_bib0072 10.1016/j.clml.2022.01.011_bib0071 Peterson (10.1016/j.clml.2022.01.011_bib0069) 2020; 54 10.1016/j.clml.2022.01.011_bib0078 10.1016/j.clml.2022.01.011_bib0077 Popat (10.1016/j.clml.2022.01.011_bib0081) 2016; 3 Moreau (10.1016/j.clml.2022.01.011_bib0046) 2016; 374 Dhakal (10.1016/j.clml.2022.01.011_bib0048) 2019; 9 Siegel (10.1016/j.clml.2022.01.011_bib0002) 2016; 66 San-Miguel (10.1016/j.clml.2022.01.011_bib0025) 2013; 14 Becnel (10.1016/j.clml.2022.01.011_bib0113) 2020; 136 Usmani (10.1016/j.clml.2022.01.011_bib0059) 2021; 147 Jakubowiak (10.1016/j.clml.2022.01.011_bib0075) 2019; 186 Kansagra (10.1016/j.clml.2022.01.011_bib0091) 2020; 136 Chow (10.1016/j.clml.2022.01.011_bib0016) 2013; 43 Ocio (10.1016/j.clml.2022.01.011_bib0022) 2015; 29 Lin (10.1016/j.clml.2022.01.011_bib0092) 2020; 136 Richardson (10.1016/j.clml.2022.01.011_bib0102) 2021; 39 Shah (10.1016/j.clml.2022.01.011_bib0029) 2015; 126 10.1016/j.clml.2022.01.011_bib0042 Usmani (10.1016/j.clml.2022.01.011_bib0062) 2019; 134 Salcedo (10.1016/j.clml.2022.01.011_bib0076) 2020; 20 10.1016/j.clml.2022.01.011_bib0041 Kumar (10.1016/j.clml.2022.01.011_bib0007) 2017; 31 Moreau (10.1016/j.clml.2022.01.011_bib0001) 2017; 28 Sonneveld (10.1016/j.clml.2022.01.011_bib0030) 2018; 132 Krishnan (10.1016/j.clml.2022.01.011_bib0031) 2018; 32 10.1016/j.clml.2022.01.011_bib0047 Berdeja (10.1016/j.clml.2022.01.011_bib0083) 2015; 100 10.1016/j.clml.2022.01.011_bib0045 Richardson (10.1016/j.clml.2022.01.011_bib0115) 2018; 8 Richardson (10.1016/j.clml.2022.01.011_bib0028) 2019; 20 10.1016/j.clml.2022.01.011_bib0053 Mikhael (10.1016/j.clml.2022.01.011_bib0008) 2019; 37 Chari (10.1016/j.clml.2022.01.011_bib0070) 2019; 381 Chari (10.1016/j.clml.2022.01.011_bib0061) 2019; 134 Borrello (10.1016/j.clml.2022.01.011_bib0004) 2012; 36 10.1016/j.clml.2022.01.011_bib0057 10.1016/j.clml.2022.01.011_bib0056 Lonial (10.1016/j.clml.2022.01.011_bib0094) 2020; 21 Farooq (10.1016/j.clml.2022.01.011_bib0107) 2020; 9 10.1016/j.clml.2022.01.011_bib0054 |
| References_xml | – reference: Karyopharm. Xpovio – reference: (belantamab mafodotin) Prescribing Information. Available at: – volume: 62 start-page: 1841 year: 2013 end-page: 1849 ident: bib0051 article-title: Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC publication-title: Cancer Immunol Immunother – volume: 21 start-page: 1330 year: 2015 end-page: 1334 ident: bib0015 article-title: Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma publication-title: Biol Blood Marrow Transplant – reference: Nooka A.K., Stockerl-Goldstein K., Quach H., DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). Oral presentation at: the American Society of Clinical Oncology Annual Meeting; May 29–31, 2020. Abstract 8502. – volume: 134 start-page: 421 year: 2019 end-page: 431 ident: bib0061 article-title: Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma publication-title: Blood – reference: Lonial S., Lee H.C., Badros A., DREAMM-2: Single-agent belantamab mafodotin (Belamaf) in patients with relapsed/refractory multiple myeloma (RRMM) –1-year outcomes by prior therapies. Poster presentation at: the American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020. Poster 1417. – volume: 8 start-page: 109 year: 2018 ident: bib0115 article-title: Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting publication-title: Blood Cancer J – reference: GlaxoSmithKline (Ireland) Limited. Blenrep – volume: 125 start-page: 2991 year: 2019 end-page: 3000 ident: bib0110 article-title: Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients publication-title: Cancer – volume: 29 start-page: 705 year: 2015 end-page: 714 ident: bib0022 article-title: In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone publication-title: Leukemia – volume: 128 start-page: 497 year: 2016 end-page: 503 ident: bib0026 article-title: Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma publication-title: Blood – volume: 32 start-page: 587 year: 2014 end-page: 600 ident: bib0013 article-title: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation publication-title: J Clin Oncol – volume: 147 start-page: 619 year: 2021 end-page: 631 ident: bib0059 article-title: Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results publication-title: J Cancer Res Clin Oncol – volume: 379 start-page: 1811 year: 2018 end-page: 1822 ident: bib0032 article-title: Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma publication-title: N Engl J Med – reference: Sanofi-Aventis Groupe. Sarclisa – volume: 126 start-page: 2284 year: 2015 end-page: 2290 ident: bib0029 article-title: Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma publication-title: Blood – reference: Takeda Pharmaceutical Company Limited. Ninlaro – volume: 34 start-page: 3286 year: 2020 end-page: 3297 ident: bib0036 article-title: Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment publication-title: Leukemia – reference: (belantamab mafodotin) Summary of Product Characteristics. Available at: – reference: (carfilzomib) Prescribing Information. Available at: https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf. Accessed August 4, 2021. – volume: 100 start-page: 670 year: 2015 end-page: 676 ident: bib0083 article-title: Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma publication-title: Haematologica – volume: 3 year: 2016 ident: bib0081 article-title: Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial publication-title: Lancet Haematol – volume: 132 start-page: 801 year: 2018 ident: bib0030 article-title: Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. The EMN011 trial publication-title: Blood – volume: 134 start-page: 927 year: 2019 ident: bib0090 article-title: Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy publication-title: Blood – volume: 2 start-page: 626 year: 2019 end-page: 627 ident: bib0033 article-title: Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: Efficacy results after additional follow-up of the phase 2, randomized ELOQUENT-3 study publication-title: HemaSphere – reference: Dimopoulos M.A., Quach H., Mateos M.-V., Carfilzomib, Dexamethasone, and Daratumumab Vs. Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. Poster presentation at: the American Society of Hematology (ASH) Annual Meeting & Exposition. December 5–8, 2020. Poster 2325. – volume: 387 start-page: 1551 year: 2016 end-page: 1560 ident: bib0058 article-title: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial publication-title: Lancet – volume: 30 start-page: 399 year: 2016 end-page: 408 ident: bib0068 article-title: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide publication-title: Leukemia – volume: 172 start-page: 889 year: 2016 end-page: 901 ident: bib0023 article-title: Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma publication-title: Br. J. Haematol – volume: 136 start-page: 22 year: 2020 end-page: 25 ident: bib0084 article-title: CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma publication-title: Blood – volume: 20 start-page: 405 year: 2015 end-page: 409 ident: bib0014 article-title: Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study publication-title: Hematology – reference: Bristol Myers Squibb. ABECMA – reference: (panobinostat) Prescribing Information. Available at: – reference: . Accessed June 4, 2021. – volume: 43 start-page: 156 year: 2013 end-page: 161 ident: bib0016 article-title: Relapsed multiple myeloma: who benefits from salvage autografts? publication-title: Intern Med J – volume: 17 start-page: 1454 year: 2018 end-page: 1463 ident: bib0052 article-title: Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab publication-title: Mol Cancer Ther – volume: 18 start-page: 154 year: 2019 ident: bib0093 article-title: Recent updates on CAR T clinical trials for multiple myeloma publication-title: Mol Cancer – volume: 2017 start-page: 508 year: 2017 end-page: 517 ident: bib0011 article-title: Management of multiple myeloma in the relapsed/refractory patient publication-title: Hematology Am Soc Hematol Educ Program – reference: Secura Bio Limited. Farydak – reference: (pomalidomide) Summary of Product Characteristics. Available at: – reference: Chen C.I., Bahlis N.J., Gasparetto C., Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM). Oral presentation at: the American Society of Hematology (ASH) Annual Meeting & Exposition. December 5–8, 2020. Abstract 726. – reference: . Accessed July 2, 2020. – volume: 134 start-page: 1888 year: 2019 ident: bib0103 article-title: Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma publication-title: Blood – volume: 136 start-page: 27 year: 2020 ident: bib0098 article-title: Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) publication-title: Blood – volume: 38 start-page: 8505 year: 2020 ident: bib0089 article-title: Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma publication-title: J Clin Oncol – volume: 38 start-page: 8500 year: 2020 ident: bib0101 article-title: First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) publication-title: J Clin Oncol – volume: 9 start-page: 56 year: 2019 ident: bib0048 article-title: Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma publication-title: Blood Cancer J – reference: (elotuzumab) Prescribing Information. Available at: – reference: GlaxoSmithKline. Blenrep – volume: 394 start-page: 2096 year: 2019 end-page: 2107 ident: bib0038 article-title: Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study publication-title: Lancet – volume: 136 start-page: 26 year: 2020 end-page: 27 ident: bib0091 article-title: Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma publication-title: Blood – volume: 131 start-page: 464 year: 2018 end-page: 467 ident: bib0112 article-title: The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents publication-title: Blood – reference: (isatuximab) Prescribing Information. Available at: – volume: 21 start-page: 207 year: 2020 end-page: 221 ident: bib0094 article-title: Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study publication-title: Lancet Oncol – volume: 33 start-page: 2266 year: 2019 end-page: 2275 ident: bib0010 article-title: Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy publication-title: Leukemia – volume: 372 start-page: 142 year: 2015 end-page: 152 ident: bib0043 article-title: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma publication-title: N Engl J Med – volume: 123 start-page: 1826 year: 2014 end-page: 1832 ident: bib0027 article-title: Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study publication-title: Blood – volume: 39 start-page: 757 year: 2021 end-page: 767 ident: bib0102 article-title: Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma publication-title: J Clin Oncol – volume: 28 year: 2017 ident: bib0001 article-title: Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – reference: (selinexor) Prescribing Information. Available at: – volume: 136 start-page: 16 year: 2020 end-page: 17 ident: bib0100 article-title: First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) publication-title: Blood – volume: 28 start-page: 2229 year: 2014 end-page: 2234 ident: bib0006 article-title: Gene expression profile alone is inadequate in predicting complete response in multiple myeloma publication-title: Leukemia – reference: Celgene. Pomalyst – volume: 396 start-page: 186 year: 2020 end-page: 197 ident: bib0063 article-title: Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study publication-title: Lancet – volume: 14 start-page: 1055 year: 2013 end-page: 1066 ident: bib0025 article-title: Pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol – volume: 7 year: 2020 ident: bib0060 article-title: Subcutaneous vs. intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial publication-title: Lancet Haematol – reference: (panobinostat) Summary of Product Characteristics. Available at: – volume: 134 year: 2019 ident: bib0062 article-title: Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): Primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688) publication-title: Blood – volume: 186 start-page: 1840 year: 2011 end-page: 1848 ident: bib0055 article-title: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors publication-title: J Immunol – volume: 38 start-page: 775 year: 2020 end-page: 783 ident: bib0096 article-title: Anti-B-Cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma publication-title: J Clin Oncol – volume: 384 start-page: 705 year: 2021 end-page: 716 ident: bib0085 article-title: Idecabtagene vicleucel in relapsed and refractory multiple myeloma publication-title: N Engl J Med – reference: (ixazomib) Summary of Product Characteristics. Available at: – volume: 186 start-page: 549 year: 2019 end-page: 560 ident: bib0075 article-title: Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma publication-title: Br J Haematol – volume: 66 start-page: 7 year: 2016 end-page: 30 ident: bib0002 article-title: Cancer statistics publication-title: CA Cancer J. Clin. – volume: 51 start-page: 479 year: 2016 end-page: 491 ident: bib0005 article-title: Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity publication-title: Bone Marrow Transplant – volume: 381 start-page: 727 year: 2019 end-page: 738 ident: bib0070 article-title: Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma publication-title: N Engl J Med – reference: National Cancer Institute. Cancer stat facts: myeloma. Available at: – reference: (daratumumab) Summary of Product Characteristics. Available at: – volume: 17 start-page: 27 year: 2016 end-page: 38 ident: bib0039 article-title: Carfilzomib and dexamethasone vs. bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study publication-title: Lancet Oncol – volume: 31 start-page: 2443 year: 2017 end-page: 2448 ident: bib0007 article-title: Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study publication-title: Leukemia – reference: Celgene. Imnovid – volume: 134 start-page: 3183 year: 2019 ident: bib0114 article-title: Elotuzumab in combination with an immunomodulatory agent (IMID) in patients with multiple myeloma refractory to IMIDs and/or daratumumab: a single-institution analysis publication-title: Blood – volume: 374 start-page: 1621 year: 2016 end-page: 1634 ident: bib0046 article-title: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med – reference: (carfilzomib) Summary of Product Characteristics. Available at: – volume: 38 start-page: 8504 year: 2020 ident: bib0087 article-title: Orvacabtagene autoleucel (orvacel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011) publication-title: J Clin Oncol – volume: 14 start-page: 2775 year: 2008 end-page: 2784 ident: bib0049 article-title: CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma publication-title: Clin Cancer Res – reference: Dimopoulos M., Delimpasi S., Simonova M., Weekly selinexor, bortezomib, and dexamethasone (SVd) vs. twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. Oral presentation at: the American Society of Clinical Oncology Annual Meeting; May 29–31, 2020. Abstract 8501. – volume: 20 start-page: 781 year: 2019 end-page: 794 ident: bib0028 article-title: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol – volume: 130 start-page: 974 year: 2017 end-page: 981 ident: bib0034 article-title: Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma publication-title: Blood – reference: (idecabtagene vicleucel) Prescribing Information. Available at: – reference: (daratumumab) Prescribing Information. Available at: – volume: 32 start-page: 1567 year: 2018 end-page: 1574 ident: bib0031 article-title: Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma publication-title: Leukemia – volume: 37 start-page: 1228 year: 2019 end-page: 1263 ident: bib0008 article-title: Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline publication-title: J Clin Oncol – reference: Karyopharm Europe GmbH. Nexpovio – volume: 30 start-page: 1005 year: 2016 end-page: 1017 ident: bib0109 article-title: Management of relapsed multiple myeloma: recommendations of the international myeloma working group publication-title: Leukemia – reference: Sanofi Genzyme. Sarclisa – volume: 136 start-page: 4 year: 2020 end-page: 6 ident: bib0116 article-title: Efficacy and safety of the panobinostat-bortezomib-dexamethasone combination in relapsed or relapsed/refractory multiple myeloma: results from the randomized PANORAMA 3 study publication-title: Blood – reference: . Accessed August 4, 2021. – volume: 12 start-page: 1473 year: 2020 ident: bib0099 article-title: BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma publication-title: Cancers (Basel) – volume: 136 start-page: 25 year: 2020 end-page: 26 ident: bib0088 article-title: Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes publication-title: Blood – reference: (pomalidomide) Prescribing Information. Available at: – reference: (selinexor) Summary of Product Characteristics. Available at: – reference: (elotuzumab) Summary of Product Characteristics. Available at: – volume: 185 start-page: 573 year: 2019 end-page: 578 ident: bib0082 article-title: Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial) publication-title: Br J Haematol – volume: 36 start-page: S3 year: 2012 end-page: 12 ident: bib0004 article-title: Can we change the disease biology of multiple myeloma? publication-title: Leuk Res – volume: 20 start-page: 1 year: 2020 end-page: 7 ident: bib0017 article-title: Treatment options for triple-class refractory multiple myeloma publication-title: Clin Lymphoma Myeloma Leuk – reference: Secura Bio. Farydak – volume: 136 start-page: 16 year: 2020 end-page: 17 ident: bib0037 article-title: Pomalidomide, dexamethasone, and daratumumab after lenalidomide treatment in relapsed refractory multiple myeloma: updated results from an open-label, multicenter, phase 2 trial publication-title: Blood – volume: 20 start-page: 198 year: 2020 end-page: 200 ident: bib0076 article-title: Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma publication-title: Clin Lymphoma Myeloma Leuk – volume: 125 start-page: 4042 year: 2015 end-page: 4051 ident: bib0021 article-title: Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets publication-title: Blood – reference: (isatuximab) Summary of Product Characteristics. Available at: – volume: 136 start-page: 45 year: 2020 end-page: 46 ident: bib0092 article-title: Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study publication-title: Blood – volume: 186 start-page: 140 year: 2019 end-page: 144 ident: bib0111 article-title: Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma publication-title: Br J Haematol – reference: (ixazomib) Prescribing Information. Available at: – reference: Bristol Myers Squibb. Empliciti – volume: 54 start-page: 577 year: 2020 end-page: 582 ident: bib0069 article-title: Selinexor: a first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma publication-title: Ann Pharmacother – volume: 22 start-page: 142 year: 2021 end-page: 154 ident: bib0080 article-title: Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study publication-title: Lancet Oncol – volume: 5 start-page: e354 year: 2015 ident: bib0019 article-title: Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 publication-title: Blood Cancer J – reference: Dimopoulos M.A., Terpos E., Boccadaro M., Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Vs. Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020; Abstract 653. – volume: 26 start-page: 2326 year: 2012 end-page: 2335 ident: bib0020 article-title: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide publication-title: Leukemia – reference: Janssen. Darzalex – reference: Moreau P., Dimopoulos M., Mikhael J., Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3, randomized, open-label study. Oral presentation at: the European Hematology Association (EHA) Annual Meeting; June 11–14, 2020. Abstract LB2603. – volume: 9 start-page: 102 year: 2016 end-page: 105 ident: bib0044 article-title: Ninlaro (Ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma publication-title: Am Health Drug Benefits – volume: 136 start-page: 20 year: 2020 end-page: 21 ident: bib0113 article-title: Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed/refractory multiple myeloma publication-title: Blood – reference: Amgen. Kyprolis – reference: National Comprehensive Cancer Network. NCCN Guidelines clinical practice guidelines in oncology: Version 2.2021 Multiple Myeloma. Version 2.2021. Available at: – volume: 122 start-page: 2331 year: 2013 end-page: 2337 ident: bib0079 article-title: PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma publication-title: Blood – volume: 11 start-page: 1155 year: 2020 ident: bib0095 article-title: Targeted Therapy With Immunoconjugates for Multiple Myeloma publication-title: Front Immunol – volume: 9 start-page: 889 year: 2020 end-page: 911 ident: bib0107 article-title: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study publication-title: Ophthalmol Ther – volume: 98 start-page: 1 year: 2019 end-page: 18 ident: bib0012 article-title: Navigating the treatment landscape in multiple myeloma: which combinations to use and when? publication-title: Ann Hematol – volume: 19 start-page: 522 year: 2019 end-page: 530 ident: bib0040 article-title: Carfilzomib-dexamethasone vs. bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups publication-title: Clin Lymphoma Myeloma Leuk – reference: Takeda Pharma A/S. Ninlaro – volume: 134 start-page: 143 year: 2019 ident: bib0097 article-title: First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial publication-title: Blood – volume: 112 start-page: 1329 year: 2008 end-page: 1337 ident: bib0050 article-title: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu publication-title: Blood – ident: 10.1016/j.clml.2022.01.011_bib0066 – volume: 22 start-page: 142 year: 2021 ident: 10.1016/j.clml.2022.01.011_bib0080 article-title: Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30680-X – volume: 20 start-page: 1 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0017 article-title: Treatment options for triple-class refractory multiple myeloma publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2019.09.621 – ident: 10.1016/j.clml.2022.01.011_bib0074 doi: 10.1200/JCO.2020.38.15_suppl.8501 – volume: 134 start-page: 421 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0061 article-title: Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma publication-title: Blood doi: 10.1182/blood.2019000722 – volume: 5 start-page: e354 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0019 article-title: Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 publication-title: Blood Cancer J doi: 10.1038/bcj.2015.66 – ident: 10.1016/j.clml.2022.01.011_bib0057 – volume: 30 start-page: 399 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0068 article-title: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide publication-title: Leukemia doi: 10.1038/leu.2015.240 – ident: 10.1016/j.clml.2022.01.011_bib0072 – volume: 186 start-page: 140 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0111 article-title: Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma publication-title: Br J Haematol doi: 10.1111/bjh.15716 – volume: 29 start-page: 705 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0022 article-title: In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone publication-title: Leukemia doi: 10.1038/leu.2014.238 – volume: 2 start-page: 626 issue: S1 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0033 article-title: Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: Efficacy results after additional follow-up of the phase 2, randomized ELOQUENT-3 study publication-title: HemaSphere doi: 10.1097/01.HS9.0000563756.72895.a3 – volume: 54 start-page: 577 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0069 article-title: Selinexor: a first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma publication-title: Ann Pharmacother doi: 10.1177/1060028019892643 – ident: 10.1016/j.clml.2022.01.011_bib0086 – volume: 34 start-page: 3286 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0036 article-title: Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment publication-title: Leukemia doi: 10.1038/s41375-020-0813-1 – ident: 10.1016/j.clml.2022.01.011_bib0054 – volume: 136 start-page: 20 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0113 article-title: Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed/refractory multiple myeloma publication-title: Blood doi: 10.1182/blood-2020-140526 – volume: 19 start-page: 522 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0040 article-title: Carfilzomib-dexamethasone vs. bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2019.04.018 – volume: 26 start-page: 2326 year: 2012 ident: 10.1016/j.clml.2022.01.011_bib0020 article-title: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide publication-title: Leukemia doi: 10.1038/leu.2012.119 – volume: 66 start-page: 7 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0002 article-title: Cancer statistics publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21332 – volume: 14 start-page: 2775 year: 2008 ident: 10.1016/j.clml.2022.01.011_bib0049 article-title: CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4246 – volume: 39 start-page: 757 year: 2021 ident: 10.1016/j.clml.2022.01.011_bib0102 article-title: Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma publication-title: J Clin Oncol doi: 10.1200/JCO.20.02259 – volume: 136 start-page: 27 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0098 article-title: Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) publication-title: Blood doi: 10.1182/blood-2020-138831 – ident: 10.1016/j.clml.2022.01.011_bib0041 – volume: 32 start-page: 587 year: 2014 ident: 10.1016/j.clml.2022.01.011_bib0013 article-title: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation publication-title: J Clin Oncol doi: 10.1200/JCO.2013.48.7934 – volume: 38 start-page: 8504 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0087 article-title: Orvacabtagene autoleucel (orvacel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011) publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.8504 – volume: 20 start-page: 781 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0028 article-title: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30152-4 – volume: 32 start-page: 1567 year: 2018 ident: 10.1016/j.clml.2022.01.011_bib0031 article-title: Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma publication-title: Leukemia doi: 10.1038/s41375-018-0038-8 – ident: 10.1016/j.clml.2022.01.011_bib0108 doi: 10.1200/JCO.2020.38.15_suppl.8502 – volume: 17 start-page: 1454 year: 2018 ident: 10.1016/j.clml.2022.01.011_bib0052 article-title: Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-17-0998 – volume: 38 start-page: 8505 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0089 article-title: Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.8505 – volume: 51 start-page: 479 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0005 article-title: Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2015.307 – volume: 100 start-page: 670 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0083 article-title: Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma publication-title: Haematologica doi: 10.3324/haematol.2014.119735 – volume: 17 start-page: 27 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0039 article-title: Carfilzomib and dexamethasone vs. bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00464-7 – volume: 8 start-page: 109 year: 2018 ident: 10.1016/j.clml.2022.01.011_bib0115 article-title: Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting publication-title: Blood Cancer J doi: 10.1038/s41408-018-0141-0 – volume: 172 start-page: 889 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0023 article-title: Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma publication-title: Br. J. Haematol doi: 10.1111/bjh.13905 – volume: 9 start-page: 56 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0048 article-title: Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma publication-title: Blood Cancer J doi: 10.1038/s41408-019-0219-3 – volume: 20 start-page: 405 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0014 article-title: Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study publication-title: Hematology doi: 10.1179/1607845414Y.0000000218 – ident: 10.1016/j.clml.2022.01.011_bib0077 – volume: 123 start-page: 1826 year: 2014 ident: 10.1016/j.clml.2022.01.011_bib0027 article-title: Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study publication-title: Blood doi: 10.1182/blood-2013-11-538835 – volume: 134 start-page: 927 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0090 article-title: Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy publication-title: Blood doi: 10.1182/blood-2019-126660 – volume: 36 start-page: S3 year: 2012 ident: 10.1016/j.clml.2022.01.011_bib0004 article-title: Can we change the disease biology of multiple myeloma? publication-title: Leuk Res doi: 10.1016/S0145-2126(12)70003-6 – ident: 10.1016/j.clml.2022.01.011_bib0106 – volume: 130 start-page: 974 year: 2017 ident: 10.1016/j.clml.2022.01.011_bib0034 article-title: Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma publication-title: Blood doi: 10.1182/blood-2017-05-785246 – volume: 98 start-page: 1 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0012 article-title: Navigating the treatment landscape in multiple myeloma: which combinations to use and when? publication-title: Ann Hematol doi: 10.1007/s00277-018-3546-8 – ident: 10.1016/j.clml.2022.01.011_bib0018 – volume: 381 start-page: 727 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0070 article-title: Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1903455 – volume: 20 start-page: 198 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0076 article-title: Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2019.12.013 – ident: 10.1016/j.clml.2022.01.011_bib0024 – ident: 10.1016/j.clml.2022.01.011_bib0047 – volume: 185 start-page: 573 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0082 article-title: Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial) publication-title: Br J Haematol doi: 10.1111/bjh.15551 – volume: 396 start-page: 186 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0063 article-title: Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(20)30734-0 – volume: 31 start-page: 2443 year: 2017 ident: 10.1016/j.clml.2022.01.011_bib0007 article-title: Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study publication-title: Leukemia doi: 10.1038/leu.2017.138 – volume: 128 start-page: 497 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0026 article-title: Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma publication-title: Blood doi: 10.1182/blood-2016-02-700872 – volume: 186 start-page: 549 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0075 article-title: Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma publication-title: Br J Haematol doi: 10.1111/bjh.15969 – volume: 21 start-page: 1330 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0015 article-title: Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2015.03.026 – volume: 379 start-page: 1811 year: 2018 ident: 10.1016/j.clml.2022.01.011_bib0032 article-title: Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1805762 – volume: 387 start-page: 1551 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0058 article-title: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01120-4 – ident: 10.1016/j.clml.2022.01.011_bib0053 – volume: 2017 start-page: 508 year: 2017 ident: 10.1016/j.clml.2022.01.011_bib0011 article-title: Management of multiple myeloma in the relapsed/refractory patient publication-title: Hematology Am Soc Hematol Educ Program doi: 10.1182/asheducation-2017.1.508 – volume: 11 start-page: 1155 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0095 article-title: Targeted Therapy With Immunoconjugates for Multiple Myeloma publication-title: Front Immunol doi: 10.3389/fimmu.2020.01155 – volume: 136 start-page: 4 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0116 article-title: Efficacy and safety of the panobinostat-bortezomib-dexamethasone combination in relapsed or relapsed/refractory multiple myeloma: results from the randomized PANORAMA 3 study publication-title: Blood doi: 10.1182/blood-2020-140697 – volume: 136 start-page: 22 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0084 article-title: CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma publication-title: Blood doi: 10.1182/blood-2020-136307 – volume: 136 start-page: 25 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0088 article-title: Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes publication-title: Blood doi: 10.1182/blood-2020-140410 – volume: 125 start-page: 2991 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0110 article-title: Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients publication-title: Cancer doi: 10.1002/cncr.32178 – volume: 14 start-page: 1055 year: 2013 ident: 10.1016/j.clml.2022.01.011_bib0025 article-title: Pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70380-2 – ident: 10.1016/j.clml.2022.01.011_bib0071 – volume: 136 start-page: 16 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0037 article-title: Pomalidomide, dexamethasone, and daratumumab after lenalidomide treatment in relapsed refractory multiple myeloma: updated results from an open-label, multicenter, phase 2 trial publication-title: Blood doi: 10.1182/blood-2020-134189 – ident: 10.1016/j.clml.2022.01.011_bib0065 – volume: 30 start-page: 1005 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0109 article-title: Management of relapsed multiple myeloma: recommendations of the international myeloma working group publication-title: Leukemia doi: 10.1038/leu.2015.356 – volume: 38 start-page: 8500 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0101 article-title: First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.8500 – ident: 10.1016/j.clml.2022.01.011_bib0009 – volume: 136 start-page: 16 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0100 article-title: First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) publication-title: Blood doi: 10.1182/blood-2020-137743 – volume: 7 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0060 article-title: Subcutaneous vs. intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial publication-title: Lancet Haematol doi: 10.1016/S2352-3026(20)30070-3 – volume: 122 start-page: 2331 year: 2013 ident: 10.1016/j.clml.2022.01.011_bib0079 article-title: PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma publication-title: Blood doi: 10.1182/blood-2013-01-481325 – volume: 33 start-page: 2266 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0010 article-title: Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy publication-title: Leukemia doi: 10.1038/s41375-019-0435-7 – volume: 134 start-page: 143 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0097 article-title: First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial publication-title: Blood doi: 10.1182/blood-2019-122895 – volume: 38 start-page: 775 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0096 article-title: Anti-B-Cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma publication-title: J Clin Oncol doi: 10.1200/JCO.19.02657 – volume: 186 start-page: 1840 year: 2011 ident: 10.1016/j.clml.2022.01.011_bib0055 article-title: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors publication-title: J Immunol doi: 10.4049/jimmunol.1003032 – volume: 18 start-page: 154 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0093 article-title: Recent updates on CAR T clinical trials for multiple myeloma publication-title: Mol Cancer doi: 10.1186/s12943-019-1092-1 – ident: 10.1016/j.clml.2022.01.011_bib0104 – volume: 147 start-page: 619 year: 2021 ident: 10.1016/j.clml.2022.01.011_bib0059 article-title: Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-020-03365-w – volume: 384 start-page: 705 year: 2021 ident: 10.1016/j.clml.2022.01.011_bib0085 article-title: Idecabtagene vicleucel in relapsed and refractory multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa2024850 – volume: 21 start-page: 207 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0094 article-title: Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30788-0 – volume: 131 start-page: 464 year: 2018 ident: 10.1016/j.clml.2022.01.011_bib0112 article-title: The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents publication-title: Blood doi: 10.1182/blood-2017-10-809293 – ident: 10.1016/j.clml.2022.01.011_bib0045 – volume: 9 start-page: 102 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0044 article-title: Ninlaro (Ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma publication-title: Am Health Drug Benefits – volume: 136 start-page: 45 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0092 article-title: Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study publication-title: Blood doi: 10.1182/blood-2020-136360 – volume: 372 start-page: 142 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0043 article-title: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1411321 – ident: 10.1016/j.clml.2022.01.011_bib0003 – ident: 10.1016/j.clml.2022.01.011_bib0078 – volume: 28 start-page: 2229 year: 2014 ident: 10.1016/j.clml.2022.01.011_bib0006 article-title: Gene expression profile alone is inadequate in predicting complete response in multiple myeloma publication-title: Leukemia doi: 10.1038/leu.2014.140 – volume: 9 start-page: 889 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0107 article-title: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study publication-title: Ophthalmol Ther doi: 10.1007/s40123-020-00280-8 – ident: 10.1016/j.clml.2022.01.011_bib0064 doi: 10.1182/blood-2020-137602 – volume: 12 start-page: 1473 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0099 article-title: BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma publication-title: Cancers (Basel) doi: 10.3390/cancers12061473 – ident: 10.1016/j.clml.2022.01.011_bib0105 – volume: 62 start-page: 1841 year: 2013 ident: 10.1016/j.clml.2022.01.011_bib0051 article-title: Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-013-1493-8 – volume: 132 start-page: 801 year: 2018 ident: 10.1016/j.clml.2022.01.011_bib0030 article-title: Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. The EMN011 trial publication-title: Blood doi: 10.1182/blood-2018-99-114029 – ident: 10.1016/j.clml.2022.01.011_bib0035 doi: 10.1182/blood-2020-135874 – ident: 10.1016/j.clml.2022.01.011_bib0042 – volume: 37 start-page: 1228 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0008 article-title: Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline publication-title: J Clin Oncol doi: 10.1200/JCO.18.02096 – volume: 112 start-page: 1329 year: 2008 ident: 10.1016/j.clml.2022.01.011_bib0050 article-title: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu publication-title: Blood doi: 10.1182/blood-2007-08-107292 – ident: 10.1016/j.clml.2022.01.011_bib0067 – volume: 43 start-page: 156 year: 2013 ident: 10.1016/j.clml.2022.01.011_bib0016 article-title: Relapsed multiple myeloma: who benefits from salvage autografts? publication-title: Intern Med J doi: 10.1111/j.1445-5994.2012.02867.x – volume: 134 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0062 article-title: Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): Primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688) publication-title: Blood doi: 10.1182/blood-2019-132629 – volume: 126 start-page: 2284 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0029 article-title: Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma publication-title: Blood doi: 10.1182/blood-2015-05-643320 – volume: 136 start-page: 26 year: 2020 ident: 10.1016/j.clml.2022.01.011_bib0091 article-title: Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma publication-title: Blood doi: 10.1182/blood-2020-134383 – volume: 374 start-page: 1621 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0046 article-title: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1516282 – volume: 134 start-page: 3183 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0114 article-title: Elotuzumab in combination with an immunomodulatory agent (IMID) in patients with multiple myeloma refractory to IMIDs and/or daratumumab: a single-institution analysis publication-title: Blood doi: 10.1182/blood-2019-129021 – volume: 134 start-page: 1888 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0103 article-title: Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma publication-title: Blood doi: 10.1182/blood-2019-126015 – ident: 10.1016/j.clml.2022.01.011_bib0056 – ident: 10.1016/j.clml.2022.01.011_bib0073 – volume: 125 start-page: 4042 year: 2015 ident: 10.1016/j.clml.2022.01.011_bib0021 article-title: Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets publication-title: Blood doi: 10.1182/blood-2014-11-611426 – volume: 28 year: 2017 ident: 10.1016/j.clml.2022.01.011_bib0001 article-title: Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdx096 – volume: 394 start-page: 2096 year: 2019 ident: 10.1016/j.clml.2022.01.011_bib0038 article-title: Isatuximab plus pomalidomide and low-dose dexamethasone vs. pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(19)32556-5 – volume: 3 year: 2016 ident: 10.1016/j.clml.2022.01.011_bib0081 article-title: Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial publication-title: Lancet Haematol doi: 10.1016/S2352-3026(16)30165-X |
| SSID | ssj0070019 |
| Score | 2.4511173 |
| SecondaryResourceType | review_article |
| Snippet | Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 460 |
| SubjectTerms | Anti-CD38 antibody Elotuzumab Heavily pretreated Immunomodulatory drugs Monoclonal antibodies Multiple myeloma Pomalidomide Proteasome inhibitors Relapsed/refractory |
| Title | Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2152265022000155 https://dx.doi.org/10.1016/j.clml.2022.01.011 https://www.ncbi.nlm.nih.gov/pubmed/35148975 https://www.proquest.com/docview/2628298456 |
| Volume | 22 |
| WOSCitedRecordID | wos000823079800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2152-2669 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0070019 issn: 2152-2650 databaseCode: AIEXJ dateStart: 20100601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6Dk17Qdwpl8lIvFVBrVM39mMFQ4DoqMSQ-hZ8C2ykadWb1n_P8S0tEx3wgFRFURI7Vb7Px7fvnIPQS1mYVEljEsJkmvRoJ014kRUJ04L0NWAui8Ilm8jOzth4zEeNxtfoC7Mus6piV1d89l-hhmsAtnWd_Qe460rhApwD6HAE2OH4d8DX0vFPXrDilIQjHz_Vyl2X363z0dqua4zmxinNjXaquNnC6OCxWMxdIp5NexgVh8ONKafBisfQBtGtstwAKeCmBWzin3P1lGb1w0wuatP_Bpgxm65Kr-0bGhv5e7pIBnb9XizgtN7_-cUdbFe--BGMkEtS0P4svon57qoF2SpcodNx1s3m001gdMB_a8f9ksLlK1VO7P4QIS62qjfLOxjOJg5E643AuM_Aci16drx1gA5JRjlrosPB-9Pxh9hb2213HpypvO7v-iuP0VGsZN_YZd_cxI1Rzu-g22FygQeeFHdRw1T30NEwyCfuo7zmBg7cwMANHLmBLTdw4AbecgNHbmDAFG-5gSM3cODGA_Tl7en563dJyLCRKJjILxNTKK4EFVmaCkq1ElwrygqSSiqljSmvoQULaMw8E2mHQbNWmouOgnK0zzoyfYia1bQyjxEmGellRvf6Bdc9mhLZh9F0RonU3FBpaAt147fLVQg_b7OglHnUGV7m9tPn9tPnnS78ui3UrsvMfPCVG59OIyR5dCuGjjAHTt1YitalwqDTDyb_WO5FRD0Hi2y32URlpqtFTvpWncBgZtJCjzwd6n8fmfRk752n6HjbXp6h5nK-Ms_RLbVeXizmJ-ggG7OTwOGfql62Hg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+Options+for+Patients+With+Heavily+Pretreated+Relapsed+and+Refractory+Multiple+Myeloma&rft.jtitle=Clinical+lymphoma%2C+myeloma+and+leukemia&rft.au=Dimopoulos%2C+Meletios-Athanasios&rft.au=Richardson%2C+Paul&rft.au=Lonial%2C+Sagar&rft.date=2022-07-01&rft.eissn=2152-2669&rft_id=info:doi/10.1016%2Fj.clml.2022.01.011&rft_id=info%3Apmid%2F35148975&rft.externalDocID=35148975 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2152-2650&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2152-2650&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2152-2650&client=summon |